Repligen News (NASDAQ:RGEN)
| Latest Repligen News Headlines | | Date | Time | Source | | | 08/07/2008 | 8:00AM | PRNUS | Repligen Reports First Quarter Fiscal Year 2009 Financial Results
WALTHAM, Mass., Aug. 7 /PRNewswire-FirstCall/ -- Repligen Corporation (NASDAQ:RGEN) today reported results for the first quarter of fiscal year 2009, ended June 30, 2008. Total revenue for the quarter was $13,660,000 compared to total revenue of $5,979,000 for the first quarter of fiscal year 2008 ended June 30, 2007... More...>> |
| 07/31/2008 | 10:27AM | PRNUS | Repligen Announces Conference Call of First Quarter Fiscal Year 2009 Results
Thursday, August 7th, 11:00 a.m. EDT
WALTHAM, Mass., July 31 /PRNewswire-FirstCall/ -- Repligen Corporation (NASDAQ:RGEN) announced today that the Company President and Chief Executive Officer, Walter C. Herlihy, Ph.D., will host a conference call and webcast on Thursday, August 7th, 2008 at 11:00 a.m. EDT, to report... More...>> |
| 07/08/2008 | 11:31AM | PRNUS | Presentation of North America's First Certificate for BS 25999, the New Standard for Business Continuity
RESTON, Va., July 8 /PRNewswire/ -- BSI announced today that Repligen Corporation, Waltham, MA (NASDAQ:RGEN); the world's leading supplier of recombinant Protein A, a consumable used in the manufacture of monoclonal antibodies, the fastest growing segment of the biopharmaceutical industry has achieved BS 25999 certification... More...>> |
| 07/08/2008 | 7:50AM | PRNUS | Repligen First in North America to Receive Certification for Business Continuity
WALTHAM, Mass., July 8 /PRNewswire-FirstCall/ -- Repligen Corporation (NASDAQ:RGEN) announced today that it is the first company in North America to receive certification to BS25999, the new standard for business continuity management. Business continuity management systems are designed to build resiliency within an... More...>> |
| 07/01/2008 | 10:02AM | PRNUS | Repligen Elects Alfred L. Goldberg, Ph.D. to the Board of Directors
WALTHAM, Mass., July 1 /PRNewswire-FirstCall/ -- Repligen Corporation (NASDAQ:RGEN) announced today that Dr. Alfred L. Goldberg, Ph.D. has been elected to its Board of Directors. Dr. Goldberg is currently a Professor of Cell Biology at Harvard Medical School. He is a renowned scientist noted in particular for elucidating... More...>> |
| 06/30/2008 | 8:00AM | PRNUS | Repligen Added to Russell 3000 Index
WALTHAM, Mass., June 30 /PRNewswire-FirstCall/ -- Repligen Corporation (NASDAQ:RGEN) announced today that it was added to the broad-market Russell 3000 Index on June 27, 2008. Annual reconstitution of Russell's U.S. indexes captures the 4,000 largest U.S. stocks as of the end of May, ranking them by total market capitalization... More...>> |
| 06/18/2008 | 7:15AM | PRNUS | Repligen Announces Share Repurchase Program
WALTHAM, Mass., June 18 /PRNewswire-FirstCall/ -- Repligen Corporation (NASDAQ:RGEN) today announced that its Board of Directors has authorized the repurchase of up to 1,250,000 shares of its common stock. Under the program Repligen may repurchase shares from time to time at prevailing prices in the open market or... More...>> |
| 06/12/2008 | 7:00AM | PRNUS | Repligen Announces Plans to Initiate a Phase 2b Trial for RG2417 in Bipolar Disorder
Reports Full Assessment of Data from Positive Phase 2a Trial
WALTHAM, Mass., June 12 /PRNewswire-FirstCall/ -- Repligen Corporation (NASDAQ:RGEN) today announced that based on feedback from the Food and Drug Administration, the Company plans to initiate a Phase 2b clinical trial of RG2417, an oral formulation of uridine... More...>> |
| 06/12/2008 | 7:00AM | PRNUS | Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
WALTHAM, Mass., June 12 /PRNewswire-FirstCall/ -- Repligen Corporation (NASDAQ:RGEN) today reported results for the fourth quarter and fiscal year 2008, ended March 31, 2008. Total revenue for fiscal year 2008 was $19,296,000 compared to total revenue of $14,074,000 for fiscal year 2007 ended March 31, 2007, an increase... More...>> |
| 06/06/2008 | 10:48AM | PRNUS | Repligen Announces Conference Call of Fourth Quarter and Fiscal Year 2008 Results
Thursday, June 12th, 11:00 a.m. EDT
WALTHAM, Mass., June 6 /PRNewswire-FirstCall/ -- Repligen Corporation (NASDAQ:RGEN) announced today that the Company President and Chief Executive Officer, Walter C. Herlihy, Ph.D., will host a conference call and webcast on Thursday, June 12th, 2008 at 11:00 a.m. EDT, to report fourth... More...>> |
| 04/16/2008 | 1:15PM | PRNUS | Repligen Receives FDA Fast Track Designation for RG1068 for Pancreatic Imaging
WALTHAM, Mass., April 16 /PRNewswire-FirstCall/ -- Repligen Corporation (NASDAQ:RGEN) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the development program for RG1068, synthetic human secretin, to improve the assessment of pancreatic duct structures by magnetic... More...>> |
| 04/08/2008 | 7:00AM | PRNUS | Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit
WALTHAM, Mass., April 8, 2008 /PRNewswire-FirstCall/ -- Repligen Corporation (NASDAQ:RGEN) announced today that it has reached a settlement with Bristol-Myers Squibb Company (NYSE:BMY) in its lawsuit alleging infringement of U.S. Patent No. 6,685,941 ("the '941 patent"), based on Bristol-Myers Squibb's sale of Orencia(R... More...>> |
| 04/07/2008 | 7:18PM | PRNUS | Repligen Announces Conference Call to Update Orencia(R) Lawsuit
Tuesday, April 8th, 9:00 a.m. EDT
WALTHAM, Mass., April 7, 2008 /PRNewswire-FirstCall/ -- Repligen Corporation (NASDAQ:RGEN) announced today that the Company President and Chief Executive Officer, Walter C. Herlihy, Ph.D., will host a conference call and webcast on Tuesday, April 8th, 2008 at 9:00 a.m. EDT, to provide... More...>> |
| 03/26/2008 | 8:00AM | PRNUS | Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging
WALTHAM, Mass., March 26 /PRNewswire-FirstCall/ -- Repligen Corporation (NASDAQ:RGEN) announced today that the Company has initiated a Phase 3 clinical trial to evaluate the use of RG1068, synthetic human secretin, to improve the assessment of pancreatic duct structures by magnetic resonance imaging (MRI). This Phase... More...>> |
| 02/07/2008 | 8:00AM | PRNUS | Repligen Reports Third Quarter Fiscal Year 2008 Financial Results
WALTHAM, Mass., Feb. 7 /PRNewswire-FirstCall/ -- Repligen Corporation (NASDAQ:RGEN) today reported results for the third quarter of fiscal year 2008, ended December 31, 2007. Total revenue for the quarter was $4,664,000 compared to $3,882,000 for the third quarter of fiscal year 2007 ended December 31, 2006, an increase... More...>> |
| 01/31/2008 | 8:00AM | PRNUS | Repligen Announces Conference Call of Third Quarter Fiscal Year 2008 Results
Thursday, February 7th, 11:00 a.m. EST
WALTHAM, Mass., Jan. 31 /PRNewswire-FirstCall/ -- Repligen Corporation (NASDAQ:RGEN) announced today that the Company President and Chief Executive Officer, Walter C. Herlihy, Ph.D., will host a conference call and webcast on Thursday, February 7th, 2008 at 11:00 a.m. EST, to report... More...>> |
| 12/13/2007 | 3:09PM | PRNUS | Repligen Elects Earl Henry, M.D. to the Board of Directors
WALTHAM, Mass., Dec. 13 /PRNewswire-FirstCall/ -- Repligen Corporation (NASDAQ:RGEN) announced today that Dr. Earl Webb Henry, M.D. has been elected to its Board of Directors. Dr. Henry is a highly experienced executive with worldwide clinical and regulatory expertise in the development of therapeutics for disorders... More...>> |
| 11/20/2007 | 9:10AM | PRNUS | Repligen to Present at Upcoming Healthcare Conferences Wednesday, November 28th and Wednesday, December 5th
WALTHAM, Mass., Nov. 20 /PRNewswire-FirstCall/ -- Repligen Corporation (NASDAQ:RGEN) announced today that the Company President and Chief Executive Officer, Walter C. Herlihy, Ph.D., will present at two upcoming healthcare conferences in New York, NY.
-- Lazard Capital Markets Fourth Annual Healthcare Conference... More...>> |
| 11/08/2007 | 7:05AM | PRNUS | Repligen Reports Second Quarter Fiscal Year 2008 Financial Results
WALTHAM, Mass., Nov. 8 /PRNewswire-FirstCall/ -- Repligen Corporation (NASDAQ:RGEN) today reported results for the second quarter of fiscal year 2008, ended September 30, 2007. Total revenue for the quarter was $5,352,000 compared to $2,865,000 for the second quarter of fiscal year 2007 ended September 30, 2006, an... More...>> |
| 11/08/2007 | 7:00AM | PRNUS | Repligen Reports Positive Phase 2a Clinical Trial Results of RG2417 for Symptoms of Bipolar Disorder
WALTHAM, Mass., Nov. 8 /PRNewswire-FirstCall/ -- Repligen Corporation (NASDAQ:RGEN) today announced positive results from a Phase 2a clinical trial of RG2417, an oral formulation of uridine, in patients with bipolar disorder. This was a multi-center study in which 84 patients received either RG2417 or a placebo twice... More...>> |
|
|
|